| 產品編號 | bs-8185R-BF594 |
| 英文名稱1 | Rabbit Anti-CRELD2/BF594 Conjugated antibody |
| 中文名稱 | BF594標記的富含半胱氨酸與表皮生長因子樣蛋白2抗體 |
| 別 名 | CREL2_HUMAN; CRELD 2; CRELD2; Cysteine rich with EGF like domain protein 2; Cysteine rich with EGF like domains 2; Cysteine-rich with EGF-like domain protein 2; DKFZp667O055; MGC11256. |
| 規格價格 | 100ul/2980元 購買 大包裝/詢價 |
| 說 明 書 | 100ul |
| 研究領域 | 細胞生物 免疫學 通道蛋白 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應 | Mouse, (predicted: Human, Rat, Chicken, Dog, Pig, Cow, Horse, Sheep, ) |
| 產品應用 | IF=1:50-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 36kDa |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human CRELD2 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存條件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 產品介紹 |
background: May regulate transport of alpha4-beta2 neuronal acetylcholine receptor. Function: May regulate transport of alpha4-beta2 neuronal acetylcholine receptor. Subunit: May interact with CHRNA4. Subcellular Location: Secreted (Potential). Endoplasmic reticulum. Tissue Specificity: Ubiquitously expressed. Similarity: Belongs to the CRELD family. Contains 2 EGF-like domains. Contains 2 FU (furin-like) repeats. Database links: UniProtKB/Swiss-Prot: Q6UXH1.1 Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| 1、抗體溶解方法 | |
| 2、抗體修復方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關于肽鏈的設計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
